BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
2/22/2019 4:33:37 AM | Browse: 1371 | Download: 2344
Publication Name World Journal of Clinical Oncology
Manuscript ID 42977
Country France
ISSN 2218-4333 (online)
Open Access This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright © The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Oncology
Manuscript Type Retrospective Cohort Study
Article Title Retrospective evaluation of FOLFIRI3 alone or in combination with bevacizumab or aflibercept in metastatic colorectal cancer
Manuscript Source Unsolicited Manuscript
All Author List Madeline Devaux, Laura Gerard, Corentin Richard, Leila Bengrine-Lefevre, Julie Vincent, Antonin Schmitt and François Ghiringhelli
ORCID
Author(s) ORCID Number
Madeline Devaux http://orcid.org/0000-0003-3220-7156
Laura Gerard http://orcid.org/0000-0003-1490-5225
Corentin Richard http://orcid.org/0000-0001-9732-0219
Leila Bengrine-Lefevre http://orcid.org/0000-0002-0762-7303-2840-9233-9444-941X-2191-6942
Julie Vincent http://orcid.org/0000-0002-4544-5033
Antonin Schmitt http://orcid.org/0000-0002-3132-7730
François Ghiringhelli http://orcid.org/0000-0002-5465-8305
Funding Agency and Grant Number
Corresponding Author François Ghiringhelli, MD, Attending Doctor, Doctor, Doctor, Professor, Department of Medical Oncology, Centre George François Leclerc, 1 Rue du Professeur Marion, Dijon 21000, France. fghiringhelli@cgfl.fr
Key Words Colorectal cancer; Chemotherapy; Irinotecan; Second-line; Aflibercept
Core Tip This retrospective study suggests that modified FOLFIRI with injection of irinotecan at day 1 and 3 is interesting for patients with previously treated metastatic colorectal cancer. Surprisingly the efficacy of the FOLFIRI3-aflibercept seems superior the FOLFIRI3 alone or in combination with bevacizumab. Prospective randomized trial comparing FOLFIRI-aflibercept to FOLFIRI3-aflibercept in second line are warranted.
Publish Date 2019-02-22 04:33
Citation Devaux M, Gerard L, Richard C, Bengrine-Lefevre L, Vincent J, Schmitt A, Ghiringhelli F. Retrospective evaluation of FOLFIRI3 alone or in combination with bevacizumab or aflibercept in metastatic colorectal cancer. World J Clin Oncol 2019; 10(2): 75-85
URL https://www.wjgnet.com/2218-4333/full/v10/i2/75.htm
DOI https://dx.doi.org/10.5306/wjco.v10.i2.75
Full Article (PDF) WJCO-10-75.pdf
Full Article (Word) WJCO-10-75.docx